<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DILTIAZEM" rxcui="3443">
<ATC code="C08DB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the diltiazem</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="D01AC15" />
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to reduction of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--with the midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended:</SEVERITY>
<COMMENT>--with the midazolam by mouth</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of midazolam by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the ombitasvir+ paritaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ROXITHROMYCIN" rxcui="9478">
<ATC code="J01FA06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Slight increase of sedation</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>353-MIDAZOLAM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.</COMMENT>
</INTERACTION>
</INTERACTIONS>
